Co-administration of nobiletin and tetrahydrocurcumin enhanced the cytotoxicity to breast cancer through inhibiting CYP1A1 enzyme: from the perspective of pharmacokinetic interactions

Abstract Background & objectives: The introduction of traditional Chinese medicine to the treatment of breast cancer increases the risk of adverse herb-herb interactions. Both nobiletin and tetrahydrocurcumin (THC) have been demonstrated to inhibit breast cancer progression, which makes them easily co-prescribed. This study evaluated the co-administration of nobiletin and THC, aiming to assess their synergistic effect in inhibiting breast cancer and reveal the potential mechanism. Materials & methods: A single dosage of nobiletin and its co-administration with THC were performed